Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sapropterin · Kuvan

Small molecule · Activator of phenylalanine hydroxylase (PAH) · developed by Biomarin Pharm

Approved FDA, Dec 2007
BMRN Developer
2 Registered trials

What is Sapropterin?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), the cofactor of phenylalanine hydroxylase (PAH). It activates residual PAH enzyme activity to improve the oxidative metabolism of phenylalanine. It is studied in GTP cyclohydrolase deficiency and in heart failure and cardiovascular disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Kuvan
Drug type
Small molecule
Targets
phenylalanine hydroxylase (PAH)
Mechanism
Activator of phenylalanine hydroxylase (PAH)
Pathways
phenylalanine hydroxylation to tyrosine
Therapy area
Cardiovascular
Developer
Biomarin Pharm (BMRN)
FDA status
Approved as Kuvan (December 13, 2007), NDA022181 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 26, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01425528 Phase 1/2 GTP Cyclohydrolase Deficiency Completed BMRN
NCT02353312 N/A Heart Failure Completed BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cardiovascular DiseaseGTP Cyclohydrolase DeficiencyHeart Failure

Other drugs acting on PAH

More from Biomarin Pharm

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.

Follow BMRN, the company behind Sapropterin

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.